Gilaberte Reyzabal, Sergio;
Isenberg, David;
(2022)
Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations.
Frontiers in Medicine
, 9
, Article 882891. 10.3389/fmed.2022.882891.
Preview |
Text
Isenberg_Differences in the development of adverse infusion reactions to Rituximab in patients with systemic lupus erythematosus DAI CLEAN CO.pdf Download (139kB) | Preview |
Abstract
It has become clear that rituximab treatment is useful for both B-cell malignancies and autoimmune rheumatic diseases. However this treatment is associated with an increased risk of an allergic reaction. We have reviewed the frequency with which these reactions occur in these different conditions. They appear to be less frequent when rituximab is used to treat rheumatoid arthritis and systemic lupus perhaps because concomitant steroids are invariably given to these patients with the rituximab which is not necessarily the case with the treatment of B-cell malignancies.
| Type: | Article |
|---|---|
| Title: | Differences in the Development of Adverse Infusion Reactions to Rituximab in Patients With Systemic Lupus Erythematosus, Rheumatoid Arthritis and Non-Hodgkin's Lymphoma-Enigma Variations |
| Location: | Switzerland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3389/fmed.2022.882891 |
| Publisher version: | http://dx.doi.org/10.3389/fmed.2022.882891 |
| Language: | English |
| Additional information: | Copyright © 2022 Gilaberte Reyzabal and Isenberg. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, systemic lupus erythematosus, rheumatoid arthritis, B-cell depletion, B-cell malignances, allergic reaction, B-CELL MALIGNANCIES, IGE ANTIBODIES, SAFETY, EFFICACY |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10152535 |
Loading...
Loading...Loading...| 1. |  China | 2 |
| 2. |  Korea, Republic of | 1 |
| 3. |  Germany | 1 |
| 4. |  Russian Federation | 1 |
| 5. |  United States | 1 |
Archive Staff Only
 |
View Item |
